Immunohistochemistry: SASH1 Antibody [NBP1-26651] - Sections of human breast carcinoma (left) and lung carcinoma (right). Antibody: Affinity purified rabbit anti- SASH1 used at a dilution of 1:1,000 (1ug/ml) and 1:400 ...read more
Immunoprecipitation: SASH1 Antibody [NBP1-26651] - Whole cell lysate (1 mg for IP, 20% of IP loaded) from HeLa cells. Antibodies: Affinity purified rabbit used for IP at 3 mcg/mg lysate. SASH1 was also ...read more
SASH1 (SAM and SH3 domain containing 1) was identified in an in silico analysis of loss of heterozygosity (LOH) to identify genes downregulated in breast cancer. Since this discovery, it has also been found to be a candidate tumor suppressor in colon cancer. Structurally, SASH1 contains two SAM (sterile alpha motif) domains and one SH3 domain indicating a role in signal transduction and as a signaling adapter.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our SASH1 Antibody and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.